UroGen’s JELMYTO shows 47.8-month median response duration in Olympus study follow-up
URGN•UroGen Pharma announced final five-year Olympus follow-up results for JELMYTO, showing a median response duration of 47.8 months among adults with low-grade upper tract urothelial cancer who achieved a complete response. No progression to high-grade disease occurred during extended follow-up.
1. Five-year follow-up
UroGen Pharma announced publication of final five-year Olympus study follow-up results for JELMYTO on Oct. 28, 2026. The results showed a median response duration of 47.8 months among adults with low-grade upper tract urothelial cancer who achieved a complete response to treatment.
2. Disease progression
No progression to high-grade disease occurred during extended follow-up. The results support JELMYTO’s role as a kidney-sparing treatment option, the company said.
